We presented data on our gene-edited therapy for people with sickle cell disease or transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Congress and announced regulatory submissions for potential future use in additional patients. Find out more:
Vertex Pharmaceuticals
3,567 posts
The official channel for Vertex Pharmaceuticals. bit.ly/3Bvj6WE
- Extended reimbursement agreement with National Health Insurance Fund in #NorthMacedonia: Since May 20, 2026, eligible people living with #CysticFibrosis ages 2 years and older have broad access to one of our medicines.
- We are proud to announce that the U.S. FDA has accepted our Biologics License Application (BLA) for our investigational therapy for #IgANephropathy. Learn more: news.vrtx.com/news-releases/…
- First reimbursement agreement in #Chile: Eligible people living with #CysticFibrosis now have reimbursed access to one of our #CysticFibrosis therapies.
- Major update for the treatment of cystic fibrosis (CF) in the U.S.: The FDA has approved the label extension for our triple combination therapies, expanding availability of these medicines to ~95% of all people with CF in the U.S. Learn more: news.vrtx.com/news-releases/…
- We’re excited to share positive topline results from the interim analysis of the RAINIER Phase 3 study of our investigational therapy for #IgANephropathy. Learn more: news.vrtx.com/news-releases/…
- We’re pleased to share results from the Phase 4 study of our non‑opioid treatment for moderate‑to‑severe acute pain, presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting: news.vrtx.com/news-releases/…
- Announcing a reimbursement agreement with the Italian Medicines Agency (AIFA) for access to our latest cystic fibrosis (CF) therapy for eligible patients 6 years and older and expanded access to two of our other medicines for eligible patients 2 years old and older.
- Vertex is committed to the safety and security of all job seekers. If you receive suspicious recruitment messages or believe you have been targeted by a recruitment scam, do not respond or provide any information. Learn how to identify recruitment scams: vrtx.com/beware-recruit…
- We have entered a new reimbursement agreement for our latest #CysticFibrosis (CF) therapy in #Bulgaria. This new agreement has enabled broad access for eligible people living with CF ages 6 years and older since Jan 5, 2026.
00:00 - Extended reimbursement agreement with the Croatian health authorities: Since Dec 30, 2025, eligible children living with #CysticFibrosis ages 1 year and older have had broad access to some of our medicines.
- We are pleased to share new data from multiple studies of our gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia at the 67th ASH Annual Meeting this weekend. Learn more: news.vrtx.com/news-releases/… #ASH25
- Extended reimbursement agreement with the health authorities of #Slovakia: eligible people living with #CysticFibrosis ages 2 year and older will now have broad access to one of our medicines.












